If you follow any longevity content online, you have heard the pitch: NAD+ is the fuel your cells run on, it drops as you age, and a supplement like NMN or NR can top it back up. The first two points are solid science. The third is where the hype outruns the evidence — many articles quietly swap impressive mouse data for thin human data and hope you do not notice. This piece does the opposite. We walked through the actual human clinical trials, one by one, to separate what has been shown in people from what has only been shown in rodents.
For the underlying biology — why NAD+ falls with age and what it does inside the cell — see our companion article on NAD+ and aging. Here, we focus narrowly on one question: when real people swallow these supplements in controlled trials, what actually happens?
A quick primer: NAD+, NMN and NR
NAD+ (nicotinamide adenine dinucleotide) is a helper molecule every cell depends on to produce energy and repair DNA. Its levels genuinely decline with age across many tissues, which is why restoring it became such an attractive target. You cannot usefully swallow NAD+ itself — it is broken down before it reaches your cells — so the supplements on the market are precursors: smaller building blocks your body converts into NAD+. The two most studied are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both have now been tested in genuine randomized, placebo-controlled human trials, which is more than can be said for most longevity supplements.
Step one is settled: these supplements do raise NAD+ in humans
The clearest, most consistent finding across the literature is that NMN and NR actually increase NAD+ in people — not just in mice. In a randomized, double-blind, placebo-controlled dose-ranging trial, 80 healthy middle-aged adults took placebo or 300, 600 or 900 mg of NMN daily for 60 days; blood NAD+ rose significantly in every NMN group, with the highest levels at 600 and 900 mg.[1] A separate Japanese trial gave 250 mg of NMN daily to healthy older men and confirmed the same thing using detailed metabolomic blood analysis.[2] On the NR side, a crossover trial in healthy middle-aged and older adults showed NR was well tolerated and effectively boosted NAD+ metabolism,[3] and a trial in aged men found that NR even raised the NAD+ metabolome inside skeletal muscle tissue, not just the bloodstream.[4] So the foundational claim — "these pills raise the molecule that declines with age" — is real and reproducible in humans.
Step two is where it gets honest: the downstream benefits are mixed
Raising NAD+ is only interesting if it translates into something you would notice. Here the picture is far more cautious. The same 80-person NMN trial reported that walking distance on a six-minute walking test improved more in the NMN groups than in placebo, best at 600 mg.[1] A six-week study in 48 recreationally trained amateur runners found that 600 and 1200 mg of NMN daily improved aerobic capacity markers during cycling tests, apparently by helping muscle use oxygen more efficiently.[5] The older-men NMN trial saw "nominally significant" improvements in gait speed and left-hand grip — the authors' own careful wording, flagging that these need confirmation in larger studies.[2]
For NR, a randomized trial found that six weeks of supplementation modestly reduced systolic blood pressure and arterial stiffness in adults with elevated readings — an encouraging cardiovascular hint, though it was a secondary finding.[3] The muscle-tissue NR trial also detected an anti-inflammatory shift in the blood.[4] These are real signals, but every one of them is small, short-term and in need of replication.
The null results matter just as much
Honest reporting means showing the trials that found nothing. A rigorous 12-week trial gave obese, insulin-resistant men 1000 mg of NR twice daily and measured insulin sensitivity with the gold-standard hyperinsulinemic-euglycemic clamp. The result was clear: no improvement in insulin sensitivity, glucose metabolism, body composition or fat handling — though it was confirmed safe.[6] The big NMN dose-ranging trial likewise found no improvement in insulin resistance scores.[1] And a 2025 systematic review and meta-analysis that pooled the randomized trials of NMN and NR in older adults reached a sobering conclusion: the current evidence does not support these supplements for preserving muscle mass, grip strength or gait speed in people over 60.[7] When you combine the studies statistically, the small individual wins largely wash out.
The one human trial that arguably moved the metabolic needle is worth singling out because it was so carefully done: a 10-week, placebo-controlled study of 250 mg NMN daily in postmenopausal women with prediabetes who were overweight or obese. Using the same clamp gold standard, it found that NMN improved muscle insulin sensitivity and insulin signaling.[8] That is a genuinely positive, well-controlled result — but it was a single trial in a specific population, and it has not yet been replicated at scale.
Why the mouse studies look so much better than the human ones
It is worth pausing on why the gap between rodent and human results is so wide, because it is the single biggest reason longevity marketing feels more exciting than the trials justify. In mice, NAD+ precursors have been linked to improved insulin sensitivity, better endurance, healthier blood vessels and even modestly longer life in some strains. Those results are real — but mice are not small humans. Laboratory mice are genetically uniform, kept in controlled conditions, and often deliberately aged or made metabolically sick so that a treatment has obvious room to help. Their metabolism runs far faster than ours, and the doses used, scaled to body weight, are frequently much higher than what people take. A compound that rescues a stressed, NAD+-depleted mouse may do very little in a reasonably healthy adult whose NAD+ is only modestly lower than it was at twenty. This is the classic translational gap, and NAD+ boosters sit squarely inside it: the biology is plausible, the animal data are encouraging, and the human payoff has so far been small and inconsistent. None of that makes the supplements useless — it simply means the honest verdict is "promising and unproven," not "clinically proven."
How to read these trials without fooling yourself
A few habits help you judge NAD+ headlines for yourself. First, separate the biomarker from the outcome you actually care about: "raised NAD+" is a biomarker, while "walked farther," "lower blood pressure" or "better insulin sensitivity" are outcomes — and a supplement can move the first without reliably moving the second. Second, watch the sample size and duration. Several of the encouraging trials enrolled only a few dozen people for six to twelve weeks, which is enough to detect a biomarker shift but far too small and brief to prove a meaningful health benefit, let alone a longevity effect. Third, note primary versus secondary findings: the blood-pressure improvement in the NR trial and the walking gains in the NMN trials were secondary or exploratory measures, which carry more risk of being chance findings than a study's pre-specified main goal. Fourth, give extra weight to meta-analyses, which pool many trials and are harder to fool — and the most recent pooled analysis in older adults came up empty for muscle and physical performance.[7] Applying these filters, the literature stops looking like a string of breakthroughs and starts looking like what it is: an early, genuinely interesting field that has not yet delivered a clear human win beyond raising the molecule itself.
What about NMN's legal status?
There is also a regulatory wrinkle worth knowing. In the United States, the FDA's position on NMN as a dietary supplement has been contested: the agency has taken the view that NMN is excluded from the supplement definition because it has been investigated as a drug, which has created ongoing uncertainty for sellers. NR's status is more settled. This does not change the science, but it explains why availability and labeling around NMN can be inconsistent, and it is a reminder that "widely sold online" is not the same as "fully regulated."
So what should you do in 2026?
Treat NMN and NR as a well-tolerated experiment with promising but unproven benefits — not as a longevity drug. The honest summary: they reliably raise NAD+ in humans, they appear safe in the doses and durations studied so far, and they show scattered early hints of benefit (endurance, blood pressure, insulin sensitivity in one specific group) alongside several solid trials that found no effect. No human study has demonstrated that they slow aging or extend lifespan, and the trials run weeks to months — far too short to answer that question.
If you decide to try one, the human-trial doses cluster around 250–600 mg per day for NMN and around 300–1000 mg for NR; choose a product verified by an independent third-party lab, because supplement quality control varies widely. Talk to your doctor first, especially if you take other medications. And keep the proportion right: across all of this research, the interventions with the strongest evidence for healthy aging remain the unglamorous ones — sleep, regular movement and a good diet do far more for you than any NAD+ capsule. If you want to understand the deeper biology of why your NAD+ falls in the first place, our NAD+ and aging explainer covers the cellular mechanism in plain language.
Common questions
Does NMN really work?
NMN reliably raises NAD+ in human blood, which is confirmed in randomized trials. Beyond that, the downstream benefits are early and mixed: some trials found small gains in walking distance, blood pressure or insulin sensitivity, while several well-run trials found nothing. No human trial has shown NMN slows aging or extends lifespan.
Is NMN safe to take?
Across the human trials done so far, both NMN and NR appear safe and well tolerated at the doses and durations studied. A rigorous 12-week NR trial in obese men confirmed safety even while finding no benefit to insulin sensitivity. Still, the trials run only weeks to months, so longer-term safety remains unproven.
How much NMN should you take?
In human trials, NMN doses cluster around 250 to 600 mg per day, and NR around 300 to 1000 mg per day. If you try one, choose a product verified by an independent third-party lab, since supplement quality control varies widely, and talk to your doctor first, especially if you take other medications.